Selective Role for Mek1 but not Mek2 in the Induction of Epidermal Neoplasia

被引:43
作者
Scholl, Florence A. [1 ,2 ]
Dumesic, Phillip A. [1 ,2 ]
Barragan, Deborah I. [1 ,2 ]
Harada, Kazutoshi [3 ]
Charron, Jean [4 ]
Khavari, Paul A. [1 ,2 ]
机构
[1] Stanford Univ, Sch Med, Program Epithelial Biol, Stanford, CA 94305 USA
[2] Vet Affairs Palo Alto Healthcare Syst, Palo Alto, CA USA
[3] Univ Yamanashi, Fac Med, Dept Dermatol, Chuo Ku, Yamanashi, Japan
[4] Univ Laval, Ctr Rech Cancerol, CHUQ, Hotel Dieu, Quebec City, PQ, Canada
关键词
RAS; ACTIVATION; MUTATION; KINASE; GROWTH;
D O I
10.1158/0008-5472.CAN-08-1963
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The Ras/Raf/Mck/Erk mitogen-activated protein kinase pathway regulates fundamental processes in normal and malignant cells, including proliferation, differentiation, and cell survival. Mutations in this pathway have been associated with carcinogenesis and developmental disorders, making Mek1 and Mek2 prime therapeutic targets. In this study, we examined the requirement for Mek1 and Mek2 in skin neoplasia using the two-step 7,12-dimethylbenz(a)anthraacene/12-O-tetradecanoylphorbol-13-acetate (DMBA/TPA) skin carcinogenesis model. Mice lacking epidermal Mek1 protein develop fewer papillomas than both wild-type and Mek2-null mice following DMBA/TPA treatment. Mek1 knockout mice had smaller papillomas, delayed tumor onset, and half the tumor burden of wild-type mice. Loss of one Mek1 allele, however, did not affect tumor development, indicating that one Mek1 allele is sufficient for normal papilloma formation. No difference in TPA-induced hyperproliferation, inflammation, or Erk activation was observed between wildtype, conditional Mek1 knockout, and Mek2-null mice, indicating that Mek1 findings were not due to a general failure of these processes. These data show that Mek1 is important for skin tumor development and that Mek2 cannot compensate for the loss of Mek1 function in this setting. [Cancer Res 2009;69(9):3772-8]
引用
收藏
页码:3772 / 3778
页数:7
相关论文
共 50 条
[31]   MEK1 promotes YAP and their interaction is critical for tumorigenesis in liver cancer [J].
Li, Lanlan ;
Wang, Jiayi ;
Zhang, Yue ;
Zhang, Yan ;
Ma, Lifang ;
Weng, Wenhao ;
Qiao, Yongxia ;
Xiao, Weifan ;
Wang, Hongmei ;
Yu, Wenjun ;
Pan, Qiuhui ;
He, Yunyan ;
Sun, Fenyong .
FEBS LETTERS, 2013, 587 (24) :3921-3927
[32]   BCL2L11 Induction Mediates Sensitivity to Src and MEK1/2 Inhibition in Thyroid Cancer [J].
Rose, Madison M. ;
Espinoza, Veronica L. ;
Hoff, Katelyn J. ;
Pike, Laura A. ;
Sharma, Vibha ;
Hofmann, Marie-Claude ;
Tan, Aik Choon ;
Pozdeyev, Nikita ;
Schweppe, Rebecca E. .
CANCERS, 2023, 15 (02)
[33]   The newly identified MEK1 tyrosine phosphorylation target MACC1 is druggable by approved MEK1 inhibitors to restrict colorectal cancer metastasis [J].
Kobelt, Dennis ;
Perez-Hernandez, Daniel ;
Fleuter, Claudia ;
Dahlmann, Mathias ;
Zincke, Fabian ;
Smith, Janice ;
Migotti, Rebekka ;
Popp, Oliver ;
Burock, Susen ;
Walther, Wolfgang ;
Dittmar, Gunnar ;
Mertins, Philipp ;
Stein, Ulrike .
ONCOGENE, 2021, 40 (34) :5286-5301
[34]   YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling [J].
Coggins, Grace E. ;
Farrel, Alvin ;
Rathi, Komal S. ;
Hayes, Colin M. ;
Scolaro, Laura ;
Rokita, Jo Lynne ;
Maris, John M. .
CANCER RESEARCH, 2019, 79 (24) :6204-6214
[35]   RDEA119/BAY 869766: A Potent, Selective, Allosteric Inhibitor of MEK1/2 for the Treatment of Cancer [J].
Iverson, Cory ;
Larson, Gary ;
Lai, Chon ;
Yeh, Li-Tain ;
Dadson, Claudia ;
Weingarten, Paul ;
Appleby, Todd ;
Vo, Todd ;
Maderna, Andreas ;
Vernier, Jean-Michel ;
Hamatake, Robert ;
Miner, Jeffrey N. ;
Quart, Barry .
CANCER RESEARCH, 2009, 69 (17) :6839-6847
[36]   MEK1 and Erk1/2 kinases as targets for the modulation of radiation responses [J].
Belka, C ;
Knippers, P ;
Rudner, J ;
Faltin, H ;
Bamberg, M ;
Budach, W .
ANTICANCER RESEARCH, 2000, 20 (5A) :3243-3249
[37]   MEK1/2 inhibition promotes Taxotere® lethality in mammary tumors in vivo [J].
Yacoub, Adly ;
Gilfor, Donna ;
Hawkins, William ;
Park, Margaret A. ;
Hanna, David ;
Hagan, Michael P. ;
Curiel, David T. ;
Fisher, Paul B. ;
Grant, Steven ;
Dent, Paul .
CANCER BIOLOGY & THERAPY, 2006, 5 (10) :1332-1339
[38]   Familial Cardiofaciocutaneous Syndrome in a Father and a Son With a Novel MEK2 Mutation [J].
Karaer, Kadri ;
Lissewski, Christina ;
Zenker, Martin .
AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2015, 167 (02) :385-388
[39]   MEK1/2 activity modulates TREM2 cell surface recruitment [J].
Schapansky, Jason ;
Grinberg, Yelena Y. ;
Osiecki, David M. ;
Freeman, Emily A. ;
Walker, Stephen G. ;
Karran, Eric ;
Gopalakrishnan, Sujatha M. ;
Talanian, Robert, V .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2021, 296
[40]   Targeted inhibition of MEK1 by cobimetinib leads to differentiation and apoptosis in neuroblastoma cells [J].
Singh, Anjali ;
Ruan, Yibing ;
Tippett, Tanya ;
Narendran, Aru .
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2015, 34